# Nebraska Advocates Celebrate DOJ Downgrade of Medical Cannabis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/doj-medical-cannabis-schedule-iii-reclassification-impact/ > **Published:** 2026-04-23T21:11:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:14:05-04:00 > **Clinical Summary:** Explore the DOJ medical cannabis Schedule III reclassification and its impact on research and clinical practice in Nebraska and beyond. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyResearchFederal Regulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Clinical Practice Why This Matters Schedule III reclassification removes the most significant federal barrier to [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), potentially enabling rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) that have been nearly impossible under Schedule I restrictions. This regulatory shift may accelerate evidence generation for specific medical conditions and dosing protocols that clinicians desperately need. Clinical Summary The DEA’s reclassification of cannabis from Schedule I to Schedule III acknowledges accepted medical use while maintaining controlled substance status. Schedule III substances have moderate to low potential for physical and psychological dependence and accepted medical applications. This change aligns federal policy more closely with state [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs and removes research barriers, though cannabis remains federally controlled and subject to prescription drug regulations. Dr. Caplan’s Take “This is the regulatory catch-up we’ve been waiting for — finally allowing the research infrastructure to build the evidence base that both patients and clinicians deserve. The real work begins now: generating the clinical data to guide proper medical use.” Clinical Perspective 🧠 Clinicians should expect increased research activity and potentially more standardized cannabis products over the coming years. However, current state medical cannabis programs continue unchanged, and this reclassification doesn’t immediately alter clinical practice recommendations. The focus should remain on existing evidence-based approaches while anticipating better data ahead. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Nebraska%20advocates%20cheer%20as%20DOJ%20downgrades%20medical%20cannabis%20to%20Schedule%20III%20drug%20%40drcaplan&url=https%3A//nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Nebraska%20advocates%20cheer%20as%20DOJ%20downgrades%20medical%20cannabis%20to%20Schedule%20III%20drug%20--%20via%20%40drcaplan.bsky.social%20https%3A//nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/](https://nebraskaexaminer.com/2026/04/23/nebraska-advocates-cheer-as-doj-downgrades-medical-cannabis-to-schedule-iii-drug/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related content does this article cover?](#What_type_of_cannabis-related_content_does_this_article_cover) - [Why is this considered “notable clinical interest”?](#Why_is_this_considered_8220notable_clinical_interest8221) - [What does the “New” label indicate?](#What_does_the_8220New8221_label_indicate) - [How does this relate to federal cannabis regulation?](#How_does_this_relate_to_federal_cannabis_regulation) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #76 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What type of cannabis-related content does this article cover? The article covers multiple aspects including policy developments, research findings, and federal regulation changes. It specifically relates to medical cannabis within the clinical context. #### Why is this considered “notable clinical interest”? The notable clinical interest designation suggests this contains emerging findings or policy developments that could impact medical practice. Healthcare providers should monitor these developments as they may influence patient care decisions. #### What does the “New” label indicate? The “New” label indicates this is recently published or updated information. This ensures healthcare professionals are aware of the most current developments in cannabis policy and research. #### How does this relate to federal cannabis regulation? The article addresses federal regulation aspects of medical cannabis, which is significant for clinical practice. Changes in federal policy can directly impact how healthcare providers can recommend or discuss cannabis treatments with patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [State-licensed medical marijuana reclassified to Schedule III drug. What it means for Kentucky – AOL](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) Learn how Kentucky's state-licensed [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) reclassification to Schedule III affects research and patient access. [Read More](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) DOJ moves to ease restrictions on [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) – NBC News An overview of the DOJ's recent efforts to ease restrictions on medical marijuana and the implications for federal policy. Explore Article [Medical marijuana reclassified: What Schedule III means for research and laws – YouTube](https://cedclinic.com/medical-marijuana-schedule-iii-research-expansion/) A detailed explanation of medical marijuana's Schedule III reclassification and its impact on research and legislation. [Watch Now](https://cedclinic.com/medical-marijuana-schedule-iii-research-expansion/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).